ZMapp is an experimental serum mixture of three humanized monoclonal antibodies for immunological protection against the Ebola virus. On 31 July 2014 the drug was first tested on humans. It was administered to two Americans who had been infected with Ebola. Both patients appeared to have had positive results.
The ZMapp drug is being developed by Mapp Biopharmaceutical Inc., a result of the collaboration between Mapp Biopharmaceutical (San Diego), LeafBio (the commercial arm of Mapp Biopharmaceutical), Defyrus Inc. (Toronto), the U.S. government and the Public Health Agency of Canada. The antibody work came out of research projects funded by the U.S. Army more than a decade ago. The Defense Threat Reduction Agency (DTRA) announced additional funds to Mapp Biopharmaceutical based on the "promising results".